Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
290,000actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-15 | actual | When the study began enrolling |
| Primary completion | 2025-08-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-15 | actual | The whole study's end, after follow-up |
| First posted | 2025-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Retinal Vasculitis
Intervention
- Drug: aflibercept 2mg — also filed as Eylea®
Primary outcomes
what the primary-completion date above is the date OFIncidence of RV events
measured During the 60-Day at-risk period following aflibercept 2 mg IVT, up to approximately 7 years
Incidence of RV plus IOI events
measured During the 60-Day at-risk period following aflibercept 2 mg IVT, up to approximately 7 years
Demographics characteristics
measured 12 months prior to the index date
Clinical characteristics: Number of participants with different retinal disease diagnosis categories
measured 12 months prior to the index date
Clinical characteristics: Mean Charlson Comorbidity Index (CCI) score
measured 12 months prior to the index date
Clinical characteristics: Summary of comorbidities reported as number of participants with different categories
measured 12 months prior to the index date
Clinical characteristics: Number of participants with prior anti-VEGF treatment
measured 12 months prior to the index date
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed